SuperworthCumberland Pharmaceuticals market cap CPIX
Share price times shares outstanding: what the whole company sells for, since 2011.
- Today, Oct 23, 2026
- $127.2M
- Highest close in our data
- $159M
- Feb 2012
Cumberland Pharmaceuticals is worth $127.2M at the close on Oct 23, 2026, at $8.49 a share.
That is up 144% over the last year and up 218% over five years.
Its highest close in our data was $159M in Feb 2012.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $127.2M | $42.3M | $127.2M | +106% |
| 2025 | $61.6M | $29.8M | $89.4M | +89% |
| 2024 | $32.6M | $14.9M | $33.4M | +28% |
| 2023 | $25.5M | $21.2M | $39.8M | −22% |
| 2022 | $32.5M | $28.6M | $63.2M | −53% |
| 2021 | $69.2M | $33M | $75.8M | +56% |
| 2020 | $44.4M | $44.4M | $80.6M | −43% |
| 2019 | $78M | $72.1M | $101M | −17% |
| 2018 | $93.5M | $82.8M | $111.8M | −19% |
| 2017 | $115.9M | $90.3M | $122.4M | +30% |
| 2016 | $89M | $70.8M | $90.4M | +3% |
| 2015 | $86.5M | $86.5M | $124.9M | −17% |
| 2014 | $104.5M | $76.3M | $104.5M | +12% |
| 2013 | $93.4M | $78M | $104.6M | +19% |
| 2012 | $78.7M | $78.7M | $159M | −27% |
| 2011 | $108.6M | $108.6M | $122.1M | n/a |
Against its peers
Companies in Drug Manufacturers - General nearest Cumberland Pharmaceuticals' size, closest first, today.
| Company | Market cap |
|---|---|
| CPIXCumberland Pharmaceuticals | $127.2M |
| NATRNatures Sunshine Products | $213.8M |
| LFVNLifevantage | $73.4M |
| SPROSpero Therapeutics | $64.6M |
| ATNMActinium Pharmaceuticals | $47.8M |
| ARVNArvinas | $477.3M |
| PBYIPuma Biotechnology | $568.9M |
| IRWDIronwood Pharmaceuticals | $571.7M |
| ZVRAZevra Therapeutics | $582.6M |
| CRMDCorMedix | $611.9M |
| COLLCollegium Pharmaceutical | $747.5M |
| Peer median | $523.1M |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on Cumberland Pharmaceuticals
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.